BD Medical Showcases Innovative Product Premieres at China International Import Expo 2021

SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Global medical technology giant BD participated in the China International Import Expo (CIIE) for the second consecutive year, actively responding to the national policy call to intensify efforts in "bringing in" and "going global" within the high-tech development sector. BD continues to advance CIIE's role as a platform hub for fostering an "open and shared" future-oriented economy in healthcare, with its exhibition scale and content achieving new highlights that surpass previous editions. With strong support from the Ministry of Commerce of China and the China International Import Expo Bureau (CIIE Bureau), BD, serving as the inaugural chairman unit of the Medical Device Professional Committee of the CIIE Exhibitor Alliance, took the lead in debuting at the newly established Innovation and Incubation Zone within the medical exhibition area. Additionally, at the unprecedentedly large Medical Enterprise Pavilion and the Public Health and Epidemic Prevention Exhibition Area, BD unveiled multiple innovative products making their China debut at this CIIE, fully demonstrating its technology-driven corporate development philosophy.2021During the China International Import Expo (CIIE), BD signed cooperation agreements with domestic medical, industrial, academic, and research partners, with a total value of RMB 270 million, setting a record high.

This year’s CIIE theme, “New Era, Shared Future,” aligns seamlessly with the core message of the inaugural “Future Healthcare” China Medical Technology Innovation Ecosystem Summit, which concluded in September and was jointly hosted by BD and the Advanced Medical Technology Association. Themed “A Journey to Renewing Patient Quality of Life Across All Scenarios, Comprehensive Ecosystem of Innovative Medical Technology Solutions,” the BD booth at the Corporate Pavilion features four major sections: “New Ecosystem for Innovative Interventions,” “Digital & Intelligent Diagnostics,” “Neurocritical & Multidisciplinary Care,” and “Smart Hospitals.” This presentation upholds BD’s development philosophy of driving industry leadership through technological innovation, while further deepening its “In China, for China” corporate strategy. By partnering with healthcare professionals, industry, academia, research institutions, and investors to co-build a new industrial ecosystem, BD is accelerating localized innovation to ultimately benefit both patients and clinical practitioners.

Deng Jianmin, Senior Vice President, Global, and General Manager, Greater China, BD, stated, “The 2021 CIIE, held against the backdrop of the inaugural year of the 14th Five-Year Plan, has provided a platform for exhibition, exchange, and trade for the high-quality transformation and development of China’s medical technology industry. BD China began implementing its localized innovation strategy many years ago, and our efforts—from building a local value chain to fostering the entire industry ecosystem—are gradually bearing fruit. We will continue to honor our commitment to the Chinese market, continuously accelerate the ‘bringing in and going global’ of innovative categories and products, contribute to the advancement of China’s medical technology industry and the enhancement of healthcare service quality, and ultimately benefit a vast number of healthcare professionals and patients across China.”

BD Senior Vice President, Global and Managing Director, Greater China Delivers Remarks at the Unveiling Ceremony of the Innovation Incubation Zone

Showcased at this year’s China International Import Expo (CIIE), BD’s “China debut” innovative products—including the FACSDuet™ integrated flow cytometry pre-processing system, the first in China to receive a Class II medical device registration certificate, and BD’s first newly launched CD127 monoclonal antibody reagent with medical registration—are ushering in a new era of standardized and automated immune monitoring in flow cytometry testing. As the inventor of the world’s first commercial flow cytometer, BD Biosciences continues to deliver healthcare solutions focused on improving clinical outcomes. The FACSDuet™ features a pioneering integrated flow cytometry workflow system that provides a one-stop solution from blood sample to results. By minimizing manual intervention, it enhances laboratory throughput and turnaround efficiency, while standardized pre-processing protocols improve data quality. Furthermore, amid recurring pandemic conditions, its unattended operation model comprehensively ensures the safety of laboratory personnel.

Multiple innovative products making their “China debut” at the 2021 CIIE, including FACSDuet™, China’s first integrated flow cytometry pre-processing system to obtain a Class II medical device registration certificate.

Following the introduction of China's first balloon-expandable vascular stent graft, LIFESTREAM™, at last year's China International Import Expo (CIIE), BD Interventional debuted the Venovo™ stent this year. Specifically designed for the iliofemoral veins, it is the world's first FDA-approved stent of its kind and was consecutively nominated for the Galen Prize—widely hailed as the "Nobel Prize of the pharmaceutical industry"—in 2020 and 2021. Approved for marketing in China through a clinical trial waiver pathway based on overseas data, this innovative product further highlights BD's comprehensive portfolio of venous solutions. Leveraging full-spectrum category advantages across the peripheral intervention market, including inferior vena cava (IVC) filters, venous stents, venous balloons, and mechanical thrombectomy devices, this portfolio delivers significant clinical benefits to over 100 million patients with lower extremity venous diseases in China.

Furthermore, the China debut of the Jiyao™ Arctic Sun 5000 Target Temperature Management (TTM) therapy system—a high-tech clinical application that "precisely controls the temperature of life"—also marks a milestone for BD China's inaugural entry into the neurosurgery field. The successful market launch of the TTM system will secure critical rescue time and save lives for patients with cardiac arrest, traumatic brain injury, neonatal hypoxia, stroke, and other conditions, while significantly improving neurological functional outcomes. Meanwhile, the newly launched Powerport Slim and Powerport Groshong implantable vascular access ports at this CIIE, along with the intraoperative surgical hemostatic product that provides physiological hemostasis—Avitene®,^®Products such as microfibrillar hemostatic collagen (large thin sponge), when integrated with cutting-edge material technologies in venous access selection and surgical procedures, further enhance patient experience, quality of life, and clinical safety. This also demonstrates BD’s innovative solutions spanning the entire care continuum—from hospital admission and diagnosis/treatment to rehabilitation—comprehensively advancing patients' quality of life.

At the BD Corporate Pavilion booth, visitors wearing HoloLens headsets can immerse themselves in the advanced medical experience enabled by innovative technology.

At the BD corporate pavilion booth, ordinary visitors can immerse themselves in the advanced medical experiences enabled by these innovative technologies. By wearing HoloLens holographic glasses, they can experience firsthand how innovative products assist surgeons in improving surgical efficiency and alleviating patient pain during various procedures (such as vascular recanalization, minimally invasive rotary excision of benign breast tumors, and hernia surgery), thereby feeling the pulse of cutting-edge technology closely integrating into healthy living and gaining a forward-looking healthcare experience.